CSIMarket Company Name, Ticker, Competitors, else..
 
Immix Biopharma Inc   (NASDAQ: IMMX)
 
Price: $13.6800 $-0.28 -2.006%
Day's High: $14.140000343322754 Week Perf: -1.87 %
Day's Low: $ 13.53 30 Day Perf: 43.4 %
Volume (M): 326,468 52 Wk High: $ 15.10
Volume (M$): $ 0 52 Wk Avg: $7.27
Open: $14.14 52 Wk Low: $1.94



 Market Capitalization (Millions $) 872
 Shares Outstanding (Millions) 64
 Employees 21
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -40
 Cash Flow (TTM) (Millions $) 68
 Capital Exp. (TTM) (Millions $) 1

Business Description


Immix Biopharma Inc is a biotechnology company focused on developing novel cancer immunotherapies. Their main goal is to harness the power of the immune system to effectively eliminate cancer cells. The company is engaged in the research and development of a proprietary platform technology known as the Immune-Directed Enzyme Prodrug Therapy (Immune-Directed EPT). This technology enables the targeted delivery of therapeutic enzymes to cancer cells, which then activates prodrugs to induce an immune response against the tumor. Immix Biopharma aims to develop innovative and personalized treatments that have the potential to improve patient outcomes in various types of cancers.


   Company Address: 11400 West Olympic Blvd. Los Angeles 90064 CA
   Company Phone Number: 651-8041   Stock Exchange / Ticker: NASDAQ IMMX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADCT        17.41% 
ISCO   -19.16%    
KPTI   -9.54%    
NRIX   -5.23%    
RYTM   -6.49%    
SBFM   -11.82%    
• View Complete Report
   



Clinical Study

Trailblazing Cell Therapies in Autoimmune Diseases: Immix Biopharma's Progress Update and Future Perspectives

Published Wed, Feb 21 2024 2:31 PM UTC

In the ever-evolving field of biopharmaceuticals, Immix Biopharma, a clinical-stage company, has been making remarkable strides in the development of cell therapies for autoimmune diseases. This article presents a comprehensive review of Immix Biopharma s 12-month progress update, highlighting key achievements and assessing their impact on the company s growth and future pr...
Announcement

Charting New Courses: Immix Biopharma's Proposed Public Offering of Common Stock.

Published Mon, Feb 5 2024 8:20 PM UTC

In a significant announcement made recently, Immix Biopharma Inc., a clinical-stage biopharmaceutical company pioneering in cell therapies for autoimmune disease, has declared its intention of floating an underwritten public offering of its common stock. This leading-edge move opens up a new chapter in the growth of the company, mapping out an exciting prospective pathway fo...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 3.81
PEG (TTM) -

Financial Strength Current
Quick Ratio 25.49
Working Capital Ratio 26.4
Leverage Ratio (MRQ) 0.04
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.92 $
Revenues (TTM) -
Cash Flow (TTM) 1.06 $
Cash 3.74 $
Book Value 3.59 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,900,820
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.